MENU
HRMY
AS OF
Feb 3 closing price
Price
$37.48
Change
+$10.70 (+39.96%)
Capitalization
2.16B
27 days until earnings call
Intraday BUY SELL Signals
+Compare
HRMY
Stock ticker: NASDAQ
AS OF
Feb 3 closing price
Price
$37.48
Change
+$10.70 (+39.96%)
Capitalization
2.16B

HRMY Harmony Biosciences Holdings Forecast, Technical & Fundamental Analysis

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs... Show more

HRMY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for HRMY with price predictions
Feb 02, 2026

HRMY sees its Stochastic Oscillator climbs out of oversold territory

On January 16, 2026, the Stochastic Oscillator for HRMY moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 61 instances where the indicator left the oversold zone. In of the 61 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 28, 2026. You may want to consider a long position or call options on HRMY as a result. In of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for HRMY just turned positive on February 02, 2026. Looking at past instances where HRMY's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .

HRMY moved above its 50-day moving average on February 02, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HRMY advanced for three days, in of 291 cases, the price rose further within the following month. The odds of a continued upward trend are .

HRMY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 10-day moving average for HRMY crossed bearishly below the 50-day moving average on January 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HRMY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for HRMY entered a downward trend on January 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HRMY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.584) is normal, around the industry mean (27.778). P/E Ratio (11.820) is within average values for comparable stocks, (51.342). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.892). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (2.659) is also within normal values, averaging (333.006).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HRMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
HRMY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

HRMY is expected to report earnings to fall 20.27% to 86 cents per share on March 03

Harmony Biosciences Holdings HRMY Stock Earnings Reports
Q4'25
Est.
$0.86
Q3'25
Beat
by $0.34
Q2'25
Beat
by $0.20
Q1'25
Beat
by $0.42
Q4'24
Beat
by $0.39
The last earnings report on November 04 showed earnings per share of $1.08, beating the estimate of 74 cents. With 563.16K shares outstanding, the current market capitalization sits at 2.16B.
A.I. Advisor
published General Information

General Information

a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
630 West Germantown Pike
Phone
+1 484 539-9800
Employees
246
Web
https://www.harmonybiosciences.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AEMSX18.350.24
+1.33%
abrdn Emerging Markets Instl Svc
JVSIX16.490.17
+1.04%
Janus Henderson Small-Mid Cap Value I
PAIGX26.110.15
+0.58%
T. Rowe Price International Value Eq Adv
NDVIX17.940.09
+0.50%
MFS New Discovery Value I
PBFDX39.07-0.44
-1.11%
Payson Total Return

HRMY and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, HRMY has been loosely correlated with SNBIF. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if HRMY jumps, then SNBIF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HRMY
1D Price
Change %
HRMY100%
+3.61%
SNBIF - HRMY
52%
Loosely correlated
N/A
CYTK - HRMY
37%
Loosely correlated
+3.12%
GERN - HRMY
36%
Loosely correlated
+12.41%
BMRN - HRMY
33%
Poorly correlated
+2.49%
AXON - HRMY
31%
Poorly correlated
-4.88%
More